<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03807440</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0187</org_study_id>
    <nct_id>NCT03807440</nct_id>
  </id_info>
  <brief_title>DIA_CENTRAL:T2D Treatment Pattern in Central Europe</brief_title>
  <official_title>CORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional study using existing data including medical chart review.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>T2D patients' baseline characteristics when initiating either empagliflozin - or other SGLT2i, DPP4i or GLP1a on top of current antidiabetic treatment by different HCP specialties in CEE countries</measure>
    <time_frame>at baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Burden of comorbidities (prevalence of cardiovascular disease (CVD), chronic kidney disease (CKD) and CVD/CKD risk factors) in this T2D patient population</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual treatment use in patients with and without established CVD</measure>
    <time_frame>up to 4 months</time_frame>
    <description>Established CV disease defined as acute myocardial infarction (AMI), cardiology intervention, ischemic heart disease (IHD), congestive heart failure (CHF), peripheral arterial disease (PAD), or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of socioeconomic parameters with treatment decisions</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate for GLP1a, DPP4i and SGLT2i after a follow up of approximately one year from the initial time point</measure>
    <time_frame>up to 14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for discontinuation for GLP1a, DPP4i and SGLT2i after a follow up of approximately one year from the initial time point</measure>
    <time_frame>up to 14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average duration of treatment for GLP1a, DPP4i and SGLT2i after a follow up of approximately one year from the initial time point</measure>
    <time_frame>up to 14 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4000</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Subjects with Diabetes Mellitus, Type 2</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin</description>
    <arm_group_label>Subjects with Diabetes Mellitus, Type 2</arm_group_label>
    <other_name>Jardiance® Synjardy® Trajenta® Jentadueto®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Glucose Transporter 2 inhibitor</intervention_name>
    <description>Sodium Glucose Transporter 2 inhibitor</description>
    <arm_group_label>Subjects with Diabetes Mellitus, Type 2</arm_group_label>
    <other_name>Jardiance® Synjardy® Trajenta® Jentadueto®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipeptidyl-peptidase 4 inhibitor</intervention_name>
    <description>Dipeptidyl-peptidase 4 inhibitor</description>
    <arm_group_label>Subjects with Diabetes Mellitus, Type 2</arm_group_label>
    <other_name>Jardiance® Synjardy® Trajenta® Jentadueto®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon-like peptide 1 agonist</intervention_name>
    <description>Glucagon-like peptide 1 agonist</description>
    <arm_group_label>Subjects with Diabetes Mellitus, Type 2</arm_group_label>
    <other_name>Jardiance® Synjardy® Trajenta® Jentadueto®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (18 years of age or older) with Type 2 Diabetes diagnosis, naïve to
        treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i),
        DPP4i (Dipeptidyl-peptidase 4 inhibitor) or GLP1a (Glucagon-like peptide 1 agonist) at
        index date were chosen.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent prior to participation

          2. Female and male patients age ≥ 18 years

          3. Patients with T2D diagnosis

          4. Patients who have been newly initiated (first ever use) with empagliflozin or other
             Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor
             (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December
             2018 (study index date 1)

          5. Patients have been naïve to treatment with empagliflozin or other Sodium Glucose
             Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or
             Glucagon-like peptide 1 agonist (GLP1a) at study index date 1

        Exclusion Criteria:

          1. Patients age &lt; 18 years

          2. Patients with diagnosis of other types of diabetes than T2D

          3. Patients who do not provide written consent to the terms of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexey Medvedchikov, +43180105-7896</last_name>
    <role>Study Chair</role>
    <affiliation>Alexey.Medvedchikov@Boehringer-Ingelheim.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Practice Dr. Alice Sýkorová</name>
      <address>
        <city>Bilina</city>
        <zip>418 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marie Horňáčková</name>
      <address>
        <city>Brno</city>
        <zip>62400</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michal Brada</name>
      <address>
        <city>Břeclav</city>
        <zip>69002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Buzová</name>
      <address>
        <city>Havířov</city>
        <zip>73601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaviatičová, Petra</name>
      <address>
        <city>Havířov</city>
        <zip>73601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbora Doležalová</name>
      <address>
        <city>Heřmanův Městec</city>
        <zip>53803</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radana Syslová</name>
      <address>
        <city>Hlušovice</city>
        <zip>78314</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavel Kasík</name>
      <address>
        <city>Hořovice</city>
        <zip>268 31</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr. Petr Maule</name>
      <address>
        <city>Humpolec</city>
        <zip>39601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr. Petra Vrbová</name>
      <address>
        <city>Jilemnice</city>
        <zip>51401</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice MUDr. Gita Markofová</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>36066</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr.Tomáš Edelsberger</name>
      <address>
        <city>Krnov</city>
        <zip>79401</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Śárka Drinková</name>
      <address>
        <city>Ledeč nad Sázavou</city>
        <zip>58401</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martina Košková</name>
      <address>
        <city>Mladá Boleslav</city>
        <zip>29350</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jitka Kuchařová</name>
      <address>
        <city>Mělník</city>
        <zip>27601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karel Churavý</name>
      <address>
        <city>Nový jičín</city>
        <zip>74101</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Śárka Kubánková</name>
      <address>
        <city>Nymburk</city>
        <zip>28802</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dobromila Vykoupilová</name>
      <address>
        <city>Němčice nad Hanou</city>
        <zip>79827</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agentura Science Pro spol. s.r.o.</name>
      <address>
        <city>Olomouc</city>
        <zip>772 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anna Rancová</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr.Tomáš Hrdina</name>
      <address>
        <city>Opočno</city>
        <zip>51773</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radka Nágelová</name>
      <address>
        <city>Ostrava Poruba</city>
        <zip>70800</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr. René Turčínek</name>
      <address>
        <city>Ostrava</city>
        <zip>70200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zdeněk Jankovec</name>
      <address>
        <city>Plzeň</city>
        <zip>30100</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologická a interní ambulance</name>
      <address>
        <city>Poděbrady</city>
        <zip>29001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr. Milena Peterková</name>
      <address>
        <city>Praha 2</city>
        <zip>12143</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr.Michala Pelikánová s.r.o.</name>
      <address>
        <city>Praha 4</city>
        <zip>14000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markéta Hovorková</name>
      <address>
        <city>Praha 4</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jakub Hron</name>
      <address>
        <city>Praha 4</city>
        <zip>14300</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milan Flekač</name>
      <address>
        <city>Praha 5</city>
        <zip>15000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiří Jón</name>
      <address>
        <city>Praha 5</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr. Lucie Kufová</name>
      <address>
        <city>Praha 5</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbora Diepoltová</name>
      <address>
        <city>Praha 9</city>
        <zip>19014</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDIN VK s.r.o.</name>
      <address>
        <city>Přerov</city>
        <zip>75301</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Střelka</name>
      <address>
        <city>Příbor</city>
        <zip>74258</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr. Petronela Janečková</name>
      <address>
        <city>Rumburk</city>
        <zip>40801</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr. Miroslav Lindovský</name>
      <address>
        <city>Sokolov</city>
        <zip>35601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Fialkovičová</name>
      <address>
        <city>Strakonice</city>
        <zip>38601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marek Frydrych</name>
      <address>
        <city>Třebíč</city>
        <zip>674 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubomír Kudlej</name>
      <address>
        <city>Vrchlabí</city>
        <zip>54301</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robin Urbánek</name>
      <address>
        <city>Zlín</city>
        <zip>76001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice MUDr. Marie Löblová</name>
      <address>
        <city>České Budějovice</city>
        <zip>37001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lékařský dům Géčko</name>
      <address>
        <city>České Budějovice</city>
        <zip>37011</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringer‐ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringeringelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after thesubmission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

